The real issue is the accuracy of sentinel node biopsy, given that it has shown no benefit, Dr. Thomas said. The false- negative rate has been shown to be about 13%. The false-positive rate is not known, but by extrapolating from various data sources, it can be estimated to be anywhere from 12% to 22%, and those patients are getting unnecessary lymphadenectomies.
“There is no survival advantage, and they shouldn't be looking at those other measures,” he said.
Dr. Ross, on the other hand, said he was not dismayed by the lack of a survival advantage in the trial.
“Overall it is a better way to treat patients because you are identifying and removing disease early,” he added.